The estimated Net Worth of James A Mish is at least $1.33 Milion dollars as of 30 September 2021. Mr Mish owns over 20,000 units of 22nd Century Inc stock worth over $189,847 and over the last 4 years he sold XXII stock worth over $0. In addition, he makes $1,140,872 as Chief Exec. Officer at 22nd Century Inc.
Mr has made over 3 trades of the 22nd Century Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of XXII stock worth $57,600 on 30 September 2021.
The largest trade he's ever made was buying 100,000 units of 22nd Century Inc stock on 17 November 2020 worth over $93,000. On average, Mr trades about 15,000 units every 35 days since 2020. As of 30 September 2021 he still owns at least 668,475 units of 22nd Century Inc stock.
You can see the complete history of Mr Mish stock trades at the bottom of the page.
James A. Mish is the Chief Exec. Officer at 22nd Century Inc.
As the Chief Exec. Officer of 22nd Century Inc, the total compensation of Mr Mish at 22nd Century Inc is $1,140,872. There are no executives at 22nd Century Inc getting paid more.
Mr Mish is 57, he's been the Chief Exec. Officer of 22nd Century Inc since . There are 7 older and 4 younger executives at 22nd Century Inc. The oldest executive at 22nd Century Group Inc is Roger O'Brien, 71, who is the Independent Director.
James's mailing address filed with the SEC is C/O 22ND CENTURY GROUP, INC., 500 SENECA STREET, SUITE 507, BUFFALO, NY, 14204.
Over the last 11 years, insiders at 22nd Century Inc have traded over $3,035,006 worth of 22nd Century Inc stock and bought 652,225 units worth $737,196 . The most active insiders traders include Andrew Arno, Joseph Pandolfino oraz Michael Zercher. On average, 22nd Century Inc executives and independent directors trade stock every 80 days with the average trade being worth of $16,372. The most recent stock trade was executed by Lawrence Firestone on 30 May 2024, trading 9,000 units of XXII stock currently worth $9,810.
with the mission of reducing the harm caused by smoking, 22nd century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. goodrich tobacco company and hercules pharmaceuticals are wholly-owned subsidiaries focusing on (i) premium cigarettes and potentially reduced risk tobacco products (with up to 97% less nicotine than conventional cigarettes), and (ii) the x-22 prescription smoking cessation aid in development. 22nd century's technology also allows the levels of cannabinoids to be decreased or increased in the cannabis plant.
22nd Century Inc executives and other stock owners filed with the SEC include: